Israeli-Italian partners for Covid-19 treatment

Israeli biotech Kamada (see here) has partnered Italy’s Kedrion to develop a human plasma-derived Anti-SARs-COV-2 product. Kamada will use its proprietary IgG platform technology and Kedrion will provide plasma from donors who have recovered from the virus.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *